Adebrelimab Plus Cetuximab and Chemotherapy for Patients With RAS/BRAF Wild-Type Unresectable Liver Metastases Colorectal Cancer - Trial NCT06231017
Access comprehensive clinical trial information for NCT06231017 through Pure Global AI's free database. This Phase 2 trial is sponsored by The First Affiliated Hospital of Zhengzhou University and is currently Recruiting. The study focuses on Metastatic Colorectal Cancer. Target enrollment is 36 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
The First Affiliated Hospital of Zhengzhou University
Timeline & Enrollment
Phase 2
Jan 19, 2024
Jan 19, 2026
Primary Outcome
Objective response rate (ORR)
Summary
The purpose of this study is to observe and evaluate the efficacy and safety of adebrelimab
 plus cetuximab and chemotherapy for patients with RAS/BRAF wild-type unresectable liver
 metastases colorectal cancer.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06231017
Non-Device Trial